

I. TAG-rich chylomicrons made by the SI from dietary lipids + VLDL from the liver, travel to the tissues via the bloodstream # Bage ~ VLOL & Chylomicon JI TAG + chylenicon II. While these two run in the blood stream, an enzyme called lipoprotein lipase degrades the TAG to FFAs - LPL is attached to the luminal surface of endothelia cells in capillaries It is most widely distributed in adipose skeletal cardiac tissues - which are used as a source of energy to produce ATP in the tissues or for storage III. Over time, the TAG/Cholesterol ratio will decrease (Remember that LPL has nothing to do with cholesterol), hence chylomicron >>> chylomicron remnant VLPL >>> IPL >>> LPL IV. chylomicron remnant & LDL consist mainly from cholesterol, they travel to the liver - the organ that can deal with cholesterol by consuming it to synthesise various materials. as bile acids which are released into the gut upon gallbladder emptying following meal ingestion, about 95% of them will be reabsorbed by the body Some notes :-* Cholesterol is for synthesis, while TAG is for energy * VLDL & LDL are related to each other, high VLDL means high LDL also * LPL has specific receptors on many tissues in the body (hepatic & extrahepatic tissues) as well as receptors on the macrophages, so any error in returning it to liver or if its plasma level is high, that will stimulate phagocytes to engulf LDL, resulting in transforming macrophages to foam

cells causing atherosclerosis

* HPL (good cholesterol, formed by liver), function: take up cholesterol from atherosclerotic plaques or foam cells

	Hyperlipopro einemia	t	Labs description
Poctor said : Pon't memorize it	Туре І	Familial hyperchylomicronemia	Elevated Chylomicrons and VLDL
• But keep this in your mind :-	Type IIa	Familial hypercholesterolemia	Elevated LDL only
 Iype IIa :- C Type IIb :- combined (TAG & C) 	Type IIb	Combined hyperlipidemia Ly means both TAG+C are elevated	Elevated LDL and VLDL and Triglycerides
• Type IV & Type V :- TAG 🔼	Type III (RARE)	Familial Dysbetalipoproteinemia	Increased IDL
	Type IV	Familial Hyperlipemia	Increased VLDL
	Туре V	Endogenous Hypertriglyceridemia	Increased VLDL and Chylomicrons
		· · · · · · · · · · · · · ·	
 Our body has also its own ch the liver, this process -as we re complicated, Don't panic ! we we the rate-limiting step, which i HMG-CoA by HMG-CoA reducts HMG-CoA <u>HMG-Coa</u> 	olester emembe von't go s the pro ase $\stackrel{\bullet}{\hookrightarrow} M -$	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic 	akes place in urse- is st to remember acid from
 Our body has also its own che the liver, this process -as we re complicated, Don't panic ! we we the rate-limiting step, which it HMG-CoA by HMG-CoA reducts HMG-CoA by HMG-CoA reducts HMG-CoA Magazine Adipose tissue is the main process 	olester emembe von't go s the pro ase $\stackrel{\bullet}{\longrightarrow} M -$	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic 	akes place in urse- is st to remember acid from
 Our body has also its own chathe liver, this process -as we recomplicated, Don't panic ! we wathe rate-limiting step, which it HMG-CoA by HMG-CoA reducts HMG-CoA by HMG-CoA reducts HMG-CoA MAG-CoA reducts 	olester emember on't go s the pro ase $\stackrel{\bullet}{\Longrightarrow} M -$ oducer o . synthe	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic 	akes place in urse- is st to remember acid from
 Our body has also its own che the liver, this process -as we recomplicated, Pon't panic ! we we the rate-limiting step, which is HMG-CoA by HMG-CoA reducts. HMG-CoA by HMG-CoA reducts. HMG-CoA HMG-CoA 	olester emember on't go s the pro ase $\stackrel{\bullet}{\longrightarrow} M -$ oducer o synthe	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic 	akes place in urse- is st to remember acid from
 Our body has also its own che the liver, this process -as we recomplicated, Don't panic ! we we the rate-limiting step, which it HMG-CoA by HMG-CoA reducts HMG-CoA by HMG-CoA reducts HMG-CoA MAG-CoA reducts 	olester emember on't go s the pro ase $\stackrel{\bullet}{\Longrightarrow} M -$ oducer o . synthe	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic 	akes place in urse- is st to remember acid from
 Our body has also its own che the liver, this process -as we recomplicated, Pon't panic ! we we the rate-limiting step, which i HMG-CoA by HMG-CoA reducts HMG-CoA frequencies HMG-CoA by HMG-CoA reducts HMG-CoA 	olester emember on't go s the pro ase $\stackrel{\bullet}{\hookrightarrow} M -$ oducer o synthe	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic 	akes place in urse- is st to remember acid from
 Our body has also its own chathe liver, this process -as we recomplicated, Pon't panic ! we was the rate-limiting step, which it HMG-CoA by HMG-CoA reducts. HMG-CoA by HMG-CoA reducts. HMG-CoA Magnetic for HMG-CoA reducts. 	olester emembe von't go s the pro ase $\stackrel{\bullet}{\longrightarrow} M -$ oducer o synthe	ol machinery, which t r from metabolism co through it, we need ju oduction of mevalonic ->> Cholesterol = of circulatory FFAs & i sis	akes place in urse- is st to remember acid from

Summary

Hyperlipoproteinemia means
 Iipoproteins, These lipoproteins
 consist of protein coat and a core of lipids
 Antihyperlipidemia drugs' moa is to
 decrease the production of the lipoproteins
 by decreasing the amount of lipids (TAG or C)
 So, no lipids no lipoproteins (VLDL/LDL)

Statins :- inhibit cholesterol synthesis # Fibrates :- increase TAG degradation # Niacin :- inhibits lipolysis (FA synthesis) # Bile acid-binding resins :- increase bile acids excretion # cholesterol absorption inhibitors :- (

endogenous

TAG+C

VLOL

FFA (lipolusis)

cholesterol

Chylomics

LOL

• These agents may used singly or in combination.



St	a	hi	ทร	
				Ζ.

•These agents are classified according to their efficacy to :-Intermediate statins :- Lovastatin, pravastatin, simvastatin, fluvastatin Strong :- Atorvastatin, rosuvastatin (also called High intensity statins) Very strong :- Cerivastatin

• Mostly used are Atorvastatin + Rosuvastatin (Strong against aggressive hyperlipidemia)

• Potency of these drugs is related to the side effects, and at the end of a day (with higher doses) they have similar efficacy

يعني بال strong statins بنقدر نرفع الجرعة بدون ما أخاف من زيادة الأعراض الجانبية • Different drugs, different limits to start experiencing side effects • Cerivastatin extremely potent "the most", however it has aggressive rhabdomyolysis as a side effect, so it was withdrawn from market • Lovastatin and fluvastatin are less likely to cause myopathy, so in cases which don't require high density statins you can use one of these

• They're used in hypercholesterolemia (high LDL) like in Types IIa & IIb

•MOA > they are called "HMG CoA reductase inhibitors", they inhibit cholesterol synthesis in the liver, the consequences of this inhibition are :-1- decreased VLPL secretion, which will also reduce LPL concentration 2- stimulate the synthesis of LPL receptors which will promotes uptake of LPL from blood

3- stimulate HPL synthesis which will bring the cholesterol trapped in foam cells (from the circulation) to the liver

•Side effects >

1- Myopathy :- Inhibition of Coenzyme Q10 of the ETC "electron transport chain" in muscles causing ATP depletion, related to pain and fatigue muscles, more common in females because they بشتغل بالملية . Its incidence is 7-8%. It has also a placebo effect, meaning that the incidence of side effects increase based on the drug's reputation (most common S.E)



2- rhabdomyolysis - disintegration or dissolution of muscle, elevation in CK (creatinine kinase), its incidence is 0.6 out of 10000 people, causes secretion of muscle myoglobulin results in nephrotoxicity
3- nephrotoxicity (from rhabdomyolysis and high levels of CK)
4- Biochemical abnormalities in liver function "very little", however they are contraindicated in liver cirrhosis, they also cause minor increases in AST,ALT (liver enzymes)

• <u>some notes</u> :-

1- evaluate muscles & liver function is needed by monitoring AST,ALT,CK levels

2- These agents are contraindicated during pregnancy and in nursing mothers. They also should not be used in children and teenagers.

Statins interaction >

* The catabolism of lovastatin, simvastatin, and atorvastatin proceeds chiefly through CYP3A4 (3A & 3 drugs) مجاعة عسل الحم

* Whereas that of fluvastatin and rosuvastatin is mediated by CYP2C9. *The exception is Pravastatin which is catabolized through other pathways, including sulfation

* Fibrates, especially gemfibrozil, are CYP450 inhibitors, so if you give your patient Fibrates with Statin you have to reduce the dose of Statin, so If you want to take statin with Fibrates the only one you can take is Pravastatin because it's metabolite by sulfate, So it's contraindicated with Fibrates (except for Pravastatin)

* Rifampin increases expression of CYP3A4 & CYP2C9, so you may need to increase the dose of the statin here

* Grapefruit juice inhibits CYP3A4, so plasma levels of lovastatin, simvastatin, and atorvastatin may be elevated

The doctor didn't mention anything other than rifampin and grapefruit, but there are other interactions you can read from the slide



• Fenofibrate and Gemfibrozil, Bezafibrate are derivatives of fibric acid

 These agents may used singly in the treatment of hypertriglyceridemia (high VLPL) like in Types IV & V, or in combination with statins in the treatment of combined hyperlipidemia

• MOA :- they bind to PPARs which are nuclear receptors that regulate lipid metabolism, resulting in reduction of TAG concentration by increasing the expression of lipoprotien lipase, the consequences are :-

1- rapid transport of free fatty acid from VLDL towards the adipose tissue which results in faster utilisation of VLDL towards LDL

2- The liver senses the increase in LPL so It absorbs it / Fibrates slightly decrease LPL

3- A part of peroxisome receptor effect is to increase HDL

• Adverse effect :-

a. The most common adverse effects are mild gastrointestinal disturbances b. Lithiasis Because these drugs increase biliary cholesterol excretion, there is a predisposition to the formation of gallstones c. Myositis (inflammation of a voluntary muscle) can occur (Rarely)

• <u>some notes</u> :-

* Fibrates compete with the coumarin anticoagulants (such as warfarin) for binding sites on plasma proteins.

* Not preferred to be used with statins because it inhibits CYP450 this will result in increased concentration of statin (especially gemfibrozil, it's contraindicated in combined hyperlipidemia), but in some cases like for Type Ilb(combined hyperlipidemia) we may give them together (Fenofibrate not gemfibrozil) + one of the statins (Pravastatin is most preferred) and here evaluation of muscles function is important

Niacin (vitamin B3)

 In the last decade, it was believed that the best treatment for hyperlipidemia is combination of Statin and Niacin, but It was withdrawn from market because of study which proved that increasing HPL has no value in treating hyperlipidemia Niacin is the most effective agent in increase the HPL (the good cholesterol carrier) 	
• It is used in type IIb and IV hyperlipoproteinemia, in which both VLDL and LDL are elevated .Also to treat other severe hypercholestrolemias	•
•MOA : 1- strongly inhibits lipolysis in adipose tissue - the primary producer of circulating free fatty acids - so lowering plasma VLPL & LPL 2- It increases HPL level by inhibiting the catabolism of HPL through foam cells	
 Adverse effects > hyperglycemia and hyperuricemia (as diuretics do) Peptic ulcer activation happens because of the decreased platelet count which will result in increased bleeding. Cutaneous flushing, burning and itching because niacin increases production of prostaglandins which are inflammatory mediators that cause dilation and increasing permeability of the vessels Others :- elevation of liver enzymes, GI irritation, nausea and vomiting Niacin is contraindicated in peptic ulcer patients. When you give Niacin to your patient you have to scratching of the doses which means starting with low dose and increasing it gradually and monitoring the side effects, another solution is to give your patient aspirin pill or 200mg profen per day for first two weeks because they decrease prostaglandins synthesis, however tolerance may happen 	

Bile acid-binding resins

• Cholestyramine and colestipol have significant LPL cholesterol lowering effect, although the benefit is less than those observed with statins, however, we give them with statins in those patients who don't respond well to statins alone / for patients who have extremely high hyperlipidemia

• Also they are the drugs of choice loften in combination with diet or niacin) in treating Type IIa.

•Those drugs are taken with food as bile acids will be excreted more at this time (food intake), unlike statins that is preferred to be taken at night because they inhibit the cholesterol synthesis which happens during the fasting time of sleeping (the low metabolic time of sleeping)

•<u>MOA</u> :-

• These agents are resins that bind bile acid in the intestine, forming insoluble complexes that will be excreted in the feces.

Lowering bile acid levels will trigger the conversion of cholesterol into bile acid and the end result will be :-

1- Reduction of cholesterol concentration

2- increasing the expression of LPL receptors which eventually decreases LPL (same mechanism as statins)

• In addition, they slightly increase HPL

• Adverse effects :-

 The most common side effects are gastrointestinal disturbances such as constipation and nausea.

At high doses they impair the absorption of fat soluble vitamins (AKED)
 These agents interact with the absorption of many drugs (fat soluble drugs), for example, Tetracycline, Digoxin, Warfarin, Aspirin. Therefore, those drugs should be taken at least 1 to 6 hr after resins intake

Cholesterol absorption inhibitors

 cholesterol clearance from the blood Don't interact with bile acid Very good effect when given with statins MOA :- Very limiting activity when we use it alone, but if it's combined with statins we'll have synergistic activity toward the reduction of LPL, meaning that when you inhibit cholesterol synthesis within the liver, the body will compensate by many mechanisms, such as increasing the absorption of cholesterol by the portal vein, hence this drug will inhibit this compensatory mechanism which resists the statins' effect and that's what we mean by synergism 	Ezetimibe selectively inhibit intestinal absorption of dietary and iliary cholesterol in the small intestine, resulting in an increase of
 Don't interact with bile acid Very good effect when given with statins MOA > Very limiting activity when we use it alone, but if it's combined with statins we'll have synergistic activity toward the reduction of LOL, meaning that when you inhibit cholesterol synthesis within the liver, the body will compensate by many mechanisms, such as increasing the absorption of cholesterol by the portal vein, hence this drug will inhibit this compensatory mechanism which resists the statins' effect and that's what we mean by synergism 	holesterol clearance from the blood
 Very good effect when given with statins MOA: Very limiting activity when we use it alone, but if it's combined with statins we'll have synergistic activity toward the reduction of LPL, meaning that when you inhibit cholesterol synthesis within the liver, the body will compensate by many mechanisms, such as increasing the absorption of cholesterol by the portal vein, hence this drug will inhibit this compensatory mechanism which resists the statins' effect and that's what we mean by synergism 	Pon't interact with bile acid
•MOA: •Very limiting activity when we use it alone, but if it's combined with statins we'll have synergistic activity toward the reduction of LPL, meaning that when you inhibit cholesterol synthesis within the liver, the body will compensate by many mechanisms, such as increasing the absorption of cholesterol by the portal vein, hence this drug will inhibit this compensatory mechanism which resists the statins' effect and that's what we mean by synergism	Very good effect when given with statins
LITAT 2 MATURE MERANDA 2 MIRTATINI	MOA : Very limiting activity when we use it alone, but if it's combined with tatins we'll have synergistic activity toward the reduction of LPL, leaning that when you inhibit cholesterol synthesis within the liver, he body will compensate by many mechanisms, such as increasing the bsorption of cholesterol by the portal vein, hence this drug will inhibit his compensatory mechanism which resists the statins' effect and hat's what we mean by synergiem
	ommon adverse effects are headache and/or diarrhea.

Summary

•		•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
•	•	•	•	•	•	•
						•
						•
•	•	•	•	•	•	•

TYPE OF DRUG	EFFECT ON LDL	EFFECT ON HDL	EFFECT ON TRIACYLGLYCEROLS
HMG-CoA reducatase inhibitors (statins)	ŧŧŧŧ	Ħ	H
Fibrates	ł	<u></u>	++++
Niacin	₩	ŧŧŧŧ	₩
Bile acid sequestrants	₩	t	Minimal
Cholesterol absorption inhibitor	ł	ł	ł

